Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00183261
Other study ID # AIN504/A5218
Secondary ID 10025AIN504/ACTG
Status Completed
Phase Phase 2
First received
Last updated
Start date March 2006
Est. completion date October 2010

Study information

Verified date October 2021
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the HIV vaccine MRKAd5 HIV-1 gag/pol/nef followed by treatment interruption can increase immune system function in adults with acute or recent HIV infection who have started taking anti-HIV drugs.


Description:

While the advent of highly active antiretroviral therapy (HAART) has contributed to the increasing control of HIV infection and viral replication, ultimate control of HIV infection will require the development of effective HIV-specific immunity in HIV infected individuals. Therapeutic vaccination within the earliest weeks following acute or recent HIV infection may increase the immune system's response to HIV. This study will determine whether MRKAd5 HIV-1 gag/pol/nef vaccine followed by treatment interruption can maintain viral suppression in patients with acute or recent HIV infection. The interventional part of the study will last 102 weeks. Participants will be randomly assigned to receive either MRKAd5 HIV-1 gag/pol/nef or placebo vaccine at baseline and Weeks 4 and 26. Participants must remain on HAART from study entry until Week 38. Participants whose HIV viral load rebounds two times or more above 500 copies/ml by Weeks 39 to 41 will not enter Step 2 of the study. Participants whose viral load drops to 500 copies/ml or less by Weeks 39 to 41 will enter Step 2, where they will discontinue HAART for 24 weeks. Participants in Step 2 will have plasma HIV viral loads measured every 2 weeks for the first 4 weeks and weekly for the next 3 weeks. Study participants will continue in Step 2 until they experience virologic and immunologic failure or they need to restart HAART for another reason; they will then enter Step 3, where they will reinitiate HAART. Step 3 participants will continue on HAART until Week 102. A long-term safety follow-up period will occur from Weeks 103 to 240. Timing of the study visits will be determined by which steps a participant enters. A physical exam and blood and urine collection will occur at most study visits throughout the study until Week 102. Follow-up phone calls to study participants will occur every 6 months from Week 102 until Week 240 to collect long-term safety data, including clinical status, CD4 count, and medication history. During the long-term safety follow-up, participants will also have study visits every 6 months. Visits will include medical and medication history.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date October 2010
Est. primary completion date August 2007
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Initiated HAART within 30 days of an acute or recent HIV-1 infection diagnosis. More information on this criterion can be found in the protocol. - Initiated HAART within 30 days of documented acute or recent HIV-1 infection without interruption for more than 7 days - Sustained viral suppression, defined as a viral load of 500 copies/mL or less 12 months prior to baseline with an undetectable HIV-1 RNA viral load between 60 to 7 days prior to baseline - CD4 count of 450 cells/mm3 or more OR 35% or more between 60 to 14 days prior to baseline - Ad5 neutralizing antibody titer of 200 or less at screening - Willing to follow all study procedures and schedules - Willing to interrupt HAART for at least 24 weeks following completion of the vaccination stage - Negative for hepatitis B surface antigen (HBsAg) at screening - Willing to use acceptable forms of contraception - Infected with HIV-1 subtype B, if this information is available Exclusion Criteria: - Virologic relapse, defined as 2 consecutive measurements of viral load of 500 copies/mL or more at least 7 days apart within 12 months of baseline visit - Received more than 7 days of continuous HAART other than that received within 16 days of acute or recent HIV-1 infection. Participants who received HAART as part of post-exposure prophylaxis (PEP) more than 6 months prior to the start of initial HAART may be eligible, provided that they did not acquire HIV-1 infection from the event that required PEP. - History of anaphylaxis or allergy to vaccine components, including Tris buffer, magnesium chloride, and polysorbate 80 (Tween) - History of clinically significant heart, lung, kidney, liver, pancreatic, gastrointestinal, or neurological disease that, in the opinion of the study investigator, may interfere with the study - Contraindication to intramuscular (IM) injection, such as anticoagulant therapy or thrombocytopenia - Receipt of any immune globulin or blood products within 3 months prior to baseline - Receipt of any live vaccine within 30 days prior to baseline or any inactivated vaccine within 14 days prior to baseline - Previous receipt of any HIV vaccine. Participants that were documented to have received only placebo are not excluded. - History of any AIDS-defining illness. If a participant's sole AIDS-defining illness is Kaposi's sarcoma limited to the skin and is not anticipated to require systemic chemotherapy, that participant is not excluded. - Currently receiving drugs or biologics not approved by the Food and Drug Administration (FDA) other than investigational HIV medications - Current or past participation in other studies that might alter the participant's response to the study vaccination - Use of any immunomodulatory agents, including but not limited to interleukin-2 (IL-2), granulocyte/macrophage-colony stimulating factor (GM-CSF), and systemic corticosteroids, within 30 days prior to baseline - Active alcohol or substance use that, in the investigator's opinion, may interfere with the study - Any other criteria or condition that, in the investigator's opinion, may interfere with the study - Unwilling or unable to contribute to the planned peripheral blood mononuclear cell (PBMC) blood collection - Pregnancy or breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
MRKAd5 HIV-1 gag/pol/nef
1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly
MRKAd5 HIV-1 gag/pol/nef placebo
1.0 mL administered intramuscularly

Locations

Country Name City State
American Samoa 407 Doctors CRS Surry Hills
Australia AIDS Research Initiative, Darlinghurst CRS Darlinghurst New South Wales
Australia Holdsworth House Medical Practice CRS Darlinghurst New South Wales
Australia St. Vincent's Hospital CRS Darlinghurst New South Wales
Australia Taylor Square Private Clinic CRS Darlinghurst New South Wales
Australia 407 Doctors (Australia) AIEDRP Sydney
Australia AIDS Research Initiative (Australia) AIEDRP Sydney
Australia Holdsworth House Gen. Practice (Australia) AIEDRP Sydney
Australia St. Vincent's Hosp. (Australia) AIEDRP Sydney
Australia Taylor Square Private Clinic (Australia) AIEDRP Sydney
United States Fenway Community Health Ctr. CRS Boston Massachusetts
United States Unc Aids Crs Chapel Hill North Carolina
United States UNC, Chapel Hill AIEDRP Chapel Hill North Carolina
United States Univ. of Colorado Health Sciences Ctr. AIEDRP Denver Colorado
United States Duke Univ. Med. Ctr. Adult CRS Durham North Carolina
United States Dumc Aiedrp Durham North Carolina
United States Aaron Diamond AIDS Research Ctr. AIEDRP New York New York
United States Beth Israel Med. Ctr., ACTU New York New York
United States The Miriam Hosp. ACTG CRS Providence Rhode Island
United States Washington U CRS Saint Louis Missouri
United States Ucsd Aiedrp San Diego California
United States Ucsf Aiedrp San Francisco California
United States LA Biomedical Research Institute at Harbor-UCLA AIEDRP Torrance California

Sponsors (3)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID) Acute Infection and Early Disease Research Program, AIDS Clinical Trials Group

Countries where clinical trial is conducted

United States,  American Samoa,  Australia, 

References & Publications (4)

Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, Deschenes GR, Ramanathan M Jr, Barsoum S, Vanderhoeven J, He T, Chung C, Murray J, Perelson AS, Zhang L, Ho DD. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis. 2002 Sep 1;186(5):634-43. Epub 2002 Aug 9. — View Citation

Moss RB, Brandt C, Giermakowska WK, Savary JR, Theofan G, Zanetti M, Carlo DJ, Wallace MR. HIV-specific immunity during structured antiviral drug treatment interruption. Vaccine. 2003 Mar 7;21(11-12):1066-71. — View Citation

Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis. 2000 Sep;182(3):766-75. Epub 2000 Aug 17. — View Citation

Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, Robbins GK, D'Aquila RT, Goulder PJ, Walker BD. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000 Sep 28;407(6803):523-6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Average of log10 HIV-1 RNA viral load At Weeks 58 and 63
Primary Frequency of Grade 3 or 4 systemic adverse events, the occurrence of a severe or life-threatening injection site adverse event, or death Throughout study
Secondary Distribution of plasma HIV RNA viral load At Weeks 63 and 87
Secondary Proportion of patients with controlled viremia and their respective distribution of plasma HIV RNA viral load At Weeks 63 and 87
Secondary Mean viral burden, defined as time-averaged area under the log10 HIV-1 RNA viral load curve At Weeks 63 and 87
Secondary HIV DNA levels At Weeks 30, 38, 63, and 87
Secondary HIV-1 DNA levels At Weeks 30, 38, 46, 50, 63, and 87
Secondary Magnitude and absolute change in CD4 and CD8 counts At Weeks 63 and 87
Secondary Percent and absolute change in the number of HIV-1- specific CD8 cells, as measured by interferon (IFN)-gamma Elispot assay and intracellular cytokine staining Through Week 30
Secondary Percent and absolute change in the cytokine secretion patterns and the proliferative capacity of HIV-1- specific CD4 and CD8 cells, as measured by multiparameter flow cytometry Through Week 30
Secondary Breadth and magnitude of HIV-1- specific CD4 and CD8 cell responses Throughout study
Secondary Time to reach the specified virologic or immunologic criteria for reinitiating antiretroviral therapy after treatment interruption Throughout study
Secondary Frequency of Grade 3 or 4 systemic adverse events or the occurrence of a severe or life-threatening injection site adverse event, or HIV-related events, AIDS-defining infections, and death from time of vaccination Throughout study
Secondary Cell-associated infectivity in latently infected cells At Week 63
Secondary Cell-associated infectivity at Week 63 and immunologic responses At Weeks 63 and 87
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2